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lesions.4,8-10 The evolution of available embolization
materials, particularly rapidly polymerizing agents, has
improved the ability to control or eradicate complex
arteriovenous connections. Often, multiple treatments
are necessary. The transcatheter therapy is usually
administered by a skilled interventional radiologist, with
occasional subsequent surgical resection. Frequently,
these patients are first seen by vascular surgeons, and it
is therefore imperative for the vascular surgeon to be
able to recognize vascular malformations and be familiar
with the best forms of treatment. Arteriovenous malfor-
mations may have audible bruits, hyperemic overlying
skin, palpable pulses, and thrills. Rapid venous filling
and venous hypertension are often noted. Lower arter-
ial blood pressure may be present, distal to an arteriove-
nous fistula, and this may elevate when the fistula is
compressed. Venous malformations have no audible
bruit or palpable pulsations or thrills. There is often a
soft, spongy texture on palpation, and the lesion may
decrease in size if the area is elevated and engorge if it is
placed in a dependent position. Hemodynamic changes
are less common with venous malformations.
At our institution, the departments of vascular surgery
and interventional radiology have been part of a multidis-
The management of congenital pelvic vascular malfor-
mations has been a difficult problem for decades. Surgical
treatment alone has historically been inadequate and has
often led to extensive damage to adjacent structures with
high recurrence rates.1-3 Proximal ligation of feeding ves-
sels has been particularly disastrous, resulting in continued
enlargement of the fistulae and increased recruitment of
smaller feeding and draining vessels. Several authors have
reported small series of these patients, usually with mini-
mal long-term follow-up.4-7
Superselective catheterization of feeding vessels and
the transcatheter administration of embolic agents have
been shown to be effective methods for managing these
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Objectives: Vascular malformations of the pelvis are rare and present a difficult therapeutic challenge. Surgical treatment is
notoriously difficult and carries a high likelihood of recurrence. Surgical proximal ligation of a feeding vessel may in fact be
contraindicated, because it can make subsequent transcatheter therapy impossible. The purpose of this study was to review
our results with transcatheter embolization therapy in symptomatic complex pelvic vascular malformations in 35 patients.
Methods: A retrospective review was conducted of a prospectively compiled database of all patients undergoing trans-
catheter therapy of a pelvic vascular malformation at our institution.
Results: The mean age of the patients was 34 years (range, 16 months–66 years), and 51% were male. The most com-
mon presenting symptoms included pain (59%), a visible or palpable lesion (62%), associated palpable pulsation or thrill
(44%), hemorrhage (27%), congestive heart failure (18%), and symptoms due to mass effect (35%). A significant num-
ber of patients had undergone previous, unsuccessful attempted surgical treatment of the lesion (32%). The most com-
mon type of lesion noted on arteriography was arteriovenous shunting (89%). Patients required a mean of 2.4
embolization procedures (range, 1-11 procedures) over a mean period of 23.3 months (range, 1-144 months). The
most common agents used were rapidly polymerizing acrylic adhesives. The most common vessels involved and treated
were branches of the hypogastric artery (82%). More than one procedure were performed in 20 patients (53%). Seven
were planned as staged embolizations, whereas 13 were due to residual or recurrent symptoms. Adjunctive surgical pro-
cedures were performed subsequent to embolization therapy in five patients (15%). Eighty-three percent of patients
were asymptomatic or significantly improved at a mean follow-up of 84 months (range, 1-204 months).
Conclusions: Pelvic vascular malformations are difficult to eradicate completely, and recurrences are common. Many
patients require multiple therapeutic interventions. However, most of these difficult cases have good results in the long
term. Transcatheter embolization plays a significant role in, and may be the treatment of choice for, symptomatic pelvic
vascular malformations. (J Vasc Surg 2001;33:51-5.)
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ciplinary center (the New York University Medical Center
Trunk and Extremity Vascular Anomaly Clinic) that has
treated a large volume of patients with vascular malforma-
tions. The purpose of this article is to review the immedi-
ate and long-term results of a large series of pelvic vascular
malformations treated with selective transcatheter
embolization over the last 19 years.
METHODS
A retrospective review was conducted of a prospectively
compiled database of all patients undergoing transcatheter
therapy of symptomatic pelvic vascular malformations at
New York University Medical Center from 1981-1999. We
reviewed 35 patients. Symptomatic patients were examined
clinically. If symptoms were present that warranted therapy,
an arteriogram or venogram was performed to define the
vascular anatomy and the means of possible access to the
nidus of the vascular malformation. The nidus is consid-
ered to be the most central area of the arteriovenous con-
nections within a malformation. In most cases a computed
tomographic (CT) scan was performed before intravascular
imaging. Symptoms included pain, bleeding, distal
ischemia, mass effect, and congestive heart failure.
Arterial catheters were percutaneously placed with the
Seldinger technique through the femoral artery. Venous
catheterization was performed directly into venous anom-
alies. Embolic agents used for arteriovenous malformations
included rapidly polymerizing acrylic adhesives (n-butyl
cyanoacrylate [NBCA] or isobutyl cyanoacrylate [IBCA])
and polyvinyl alcohol foam particles (Ivalon). For primarily
venous malformations, absolute alcohol was used as a scle-
rosing agent. Other embolic agents included stainless steel
or platinum coils, liquid silicone, and collagen suspension
(Avitene). General anesthesia was used in all patients dur-
ing embolization.
Follow-up consisted of repeat angiography, clinical
examination, or phone conversations with the patient or
referring physician. Phone conversations were conducted
by three of the authors (R.J.R., D.J.H., and B.F.).
Symptoms were described as worse, no improvement, or
better.
RESULTS
The mean age of the patients was 34 years (range, 16
months–66 years), and 51% were male. The presenting
symptoms are shown in Table I. Patients often had more
than one presenting symptom. The distribution of pain
location is shown in Table II.
Previous, unsuccessful surgical treatment at other insti-
tutions had been attempted in 32% of patients, and previ-
ous attempts at embolization had been made in 29% of
patients before treatment at our institution. The type of
lesion was primarily arteriovenous in 89% of patients and
primarily venous in 11%.
The embolic agents used are listed in Table III. The
most common agents were the rapidly polymerizing acrylic
adhesives and IBCA, administered by means of an arterial
injection. NBCA had been used almost exclusively in recent
years in this series for high-flow arteriovenous malforma-
tions. Venous malformations were treated with direct injec-
tion of absolute alcohol into the lesion. General anesthesia
was used in all patients to avoid the pain associated with con-
Table I. Signs and symptoms associated with pelvic 
vascular malformations
Pain 59%
Visible or palpable lesion 61%
Palpable pulsation/thrill 44%
Mass effect 35%
Hemorrhage 26%
High-output heart failure 18%
Distal ischemia 6%
Postorgasm pain 3%
Impotence 3%
Table II. Location of pain associated with pelvic vascular
malformations
Buttock 23%
Testicular 62%
Thigh 21%
Perineum 14%
Vagina 3%
Rectum 20%
Uterine 11%
Abdominal 11%
Table III. Embolization agents
Agent Delivery access Type of lesion Percent of cases used*
NBCA Arterial AV malformation 41%
IBCA Arterial AV malformation 53%
PVA Arterial AV malformation 29%
Coils† Arterial AV malformation 3%
Collagen suspension (Avitene) Arterial AV malformation 9%
Liquid silicone Arterial AV malformation 3%
Absolute alcohol Direct puncture of malformation Venous malformation 14%
*More than one agent was used in some cases.
†Stainless steel or platinum coils.
AV, Arteriovenous; IBCA, isobutyl cyanoacrylate; NBCA, n–butyl cyanoacrylate; PVA, polyvinyl alcohol foam particles.
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trast dye injections and also to prevent patient movement
during the extensive “roadmapping” required during these
procedures. Temporary neurologic deficits were not rou-
tinely noted. The embolized vessels are listed in Table IV.
The most common were branches of the internal iliac artery.
More than one procedure was performed in 20 (57%)
patients. Of these, seven were planned as staged emboliza-
tions, and 13 were due to residual or recurrent symptoms.
Patients required a mean of 2.4 embolization procedures
(range, 1-11) over a mean period of 23.3 months (range,
1-144 months). In female patients, the mean number of
embolization procedures was 3.2 (range, 1-11). The mean
number of embolizations in male patients was 1.7 (range,
1-4) (no significant difference).
Adjunctive surgical procedures were performed subse-
quent to embolization therapy in five cases (14%). All of the
cases involving surgical resection were primarily arteriovenous
malformations. Two of these procedures were hysterectomies
in patients with uterine vascular malformations; two other
procedures were for a gluteal vascular malformation and a
perineal and scrotal malformation. Another procedure was an
anterior pelvic exenteration for a large arteriovenous malfor-
mation involving the pelvis and bladder wall causing high-
output heart failure. This last case involved the one patient in
the group with a significant complication. Intractable hema-
turia developed after 11 embolization procedures over 5
years. This was most likely due to bladder ischemia.
Long-term follow-up was obtained in 34 (97%) of 35
patients, with a mean of 84.4 months (range, 4-204
months). Improvement or resolution of symptoms was
achieved in 29 (83%) of 35 patients. Two (6%) patients
had no improvement. Three (9%) patients were worse at
last follow-up. One of these three patients died, and the
death was the only one in the group that was related to
complications of the vascular malformation. This patient
was a woman who initially presented at age 24 with an
extensive pelvic vascular malformation and severe high-
output heart failure. These had been well controlled with
five embolization procedures between 1982 and 1995.
This time period included one full-term pregnancy.
Symptoms had significantly worsened during the preg-
nancy. Against medical advice, the patient had a second
full-term pregnancy, again had worsening of the high-out-
put failure, and subsequently died of her cardiomyopathy.
DISCUSSION
The circulatory connections of pelvic vascular malfor-
mations are complex. When arteriovenous malformations
are present, they are both numerous and often micro-
scopic in size. Congenital malformations are presumed to
represent a focal persistence of primitive vascular elements.
They are not true neoplasms and do not have endothelial
proliferation or cellular stroma.11,12
The natural history of vascular malformations is vari-
able. They can remain asymptomatic for years and, at times,
indefinitely. Several authors have shown that asymptomatic
lesions may be safely observed, with no intervention.4,8,13
Evaluation of the size of malformations and the location
with respect to adjacent structures can be followed with
CT scan and magnetic resonance imaging (MRI). Recent
advances in MRI technology have made this the noninva-
sive modality of choice for imaging vascular malforma-
tions.14-16 When symptoms develop, there may be pain,
mass effects such as invasion or compression of adjacent
organs, hemorrhage, high-output heart failure, impotence,
and end-organ ischemia. These symptoms will usually not
resolve without intervention. The location of pain did not
correlate with specific vessels involved in this series. This
was most likely because the pain was caused by multiple
factors, particularly mass effects, hemorrhage, or ischemia.
Attempts at primary surgical resection of pelvic vascular
malformations have been largely unsuccessful. Extirpations
and proximal ligation of large feeding vessels have been
complicated by massive hemorrhage, adjacent organ dam-
age, and recurrence with recruitment of new arteriovenous
communications.2,3,10,17 In addition, surgical therapy has
often precluded later transcatheter therapy because ligation
of the main feeding arteries has made catheter access diffi-
cult or impossible.10,18,19
The development of flexible small-caliber catheters has
allowed superselective branch vessel cannulation and
angiographic delineation of the anatomy of vascular mal-
formations. Specific feeding vessels can be identified, and
transcatheter embolization therapy can then be used with
the goal of obliterating the nidus, or center, of the mal-
formation. This has proved more effective than proximal
vessel ligation or occlusion, particularly when combined
with subsequent surgical resection.5,6,10 Embolization of
the nidus requires material that will provide permanent
occlusion of vessels at a microscopic level. Therefore,
larger or nonpermanent material such as coils, detachable
balloons, or absorbable gelatin sponges (Gelfoam) are
often ineffective. Agents used with much more success
have been polyvinyl alcohol foam particles (Ivalon) and
the rapidly polymerizing cyanoacrylate adhesives IBCA
and NBCA. In our experience, NBCA has been the most
useful agent in recent years. This material polymerizes on
contact with ionic material such as blood. It can be deliv-
ered by means of catheters directly into a vascular malfor-
mation and form a cast of the multiple small vessels near
the nidus of the malformation. This has been particularly
useful in arteriovenous malformations, where the NBCA
can rapidly polymerize in the high flow system, acting as a
glue. When polyvinyl alcohol is used, it should be with
small particles (150-500 µm), because larger particles will
occlude vessels in too proximal a position—away from the
Table IV. Arteries embolized
Internal iliac branch 83%
Inferior mesenteric branch 23%
Bilateral internal iliac 11%
Unilateral internal iliac 11%
Profunda femoris branch 17%
Common femoral branch 6%
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nidus.4 Similarly, the cyanoacrylate adhesives must be
diluted appropriately to allow for dispersion into a nidus
before polymerization.4,20 Although elimination of the
nidus is always the goal, complete obliteration is often not
achieved.
For venous malformations, absolute alcohol has been
used through direct injection into the venous lakes. The
low flow in these lesions allows the alcohol to remain at the
injection site and effectively sclerose the area. Yakes et al21
have reported success with the use of absolute alcohol in
arteriovenous connections. However, we have not used it
in intra-arterial injections because of its extreme tissue tox-
icity. Absolute alcohol injection has been associated with
skin or mucosal sloughing or permanent nerve damage in
the treatment of arteriovenous malformations.22
In female patients, these malformations tend to be
more complex, with multiple feeding arteries. Although
primary supply is usually from one or both internal iliac
arteries, additional supply is often from the inferior mesen-
teric, middle sacral, common, or deep femoral artery
branches.23 Recurrences are more common in females. As
noted previously, the mean number of embolizations was
3.2 for females compared with 1.7 for males. In the male
patient a distinctive pattern of malformation has been
noted. It is characterized by supply from one internal iliac
artery with massively dilated draining veins. The venous
component tends to be the cause of symptoms, which are
related to compression of surrounding structures causing
pelvic pain, urinary outlet obstruction, and rectal pain. The
simpler arterial blood supply in males most likely accounts
for the tendency for these lesions to respond to emboliza-
tion more favorably than in females. Alleviation or elimina-
tion of symptoms can be equally obtained in females with
transcatheter therapy, but more frequent embolizations
may be necessary. The etiology of the more complex pelvic
malformations occurring in females is unclear. It may be
related to hormonal factors that affect local angiogenic
mechanisms. As noted previously, in one of the patients in
this series, pelvic vascular malformations have enlarged and
recurred during pregnancy.
Previous articles about pelvic vascular malformations
have been limited to smaller series of patients, and in many
articles an emphasis is made on adjunctive surgical ther-
apy.4-7,23-27 These series are summarized in Table V. The
current study is the largest series to date from a single insti-
tution regarding pelvic lesions. In this series adjunctive sur-
gical therapy was performed in only five patients.
Transcatheter embolization alone, although often neces-
sary multiple times, was sufficient to eliminate or improve
symptoms in a high percentage of patients. This reflects the
palliative nature of the treatment of vascular malforma-
tions. As Szilagyi et al noted in 1976,2 it would be inaccu-
rate to claim a “cure” for most vascular malformations.
However, the high rate of recurrence can be readily treated
with additional transcatheter therapy. It is not uncommon
for many years to elapse between recurrences. Because of
the well-described high morbidity rate from surgical resec-
tion, we would recommend transcatheter embolization
therapy as the primary treatment for pelvic vascular malfor-
mations. Adjunctive surgery should be reserved for patients
with symptoms unimproved with embolization. In these
cases, surgery is indicated after evaluation of the resectabil-
ity of the malformation with respect to adjacent structures.
This can be done with a combination of angiography and
MRI or CT scanning. If the lesion is determined to be
resectable, preoperative embolization should still be per-
formed to limit surgical bleeding. If a lesion is sympto-
matically improved with embolization, no further therapy
is needed, because the return of symptoms is variable.
Furthermore, if a vascular malformation is poorly con-
trolled with embolization and surgically unresectable,
repeated transcatheter therapy may still offer the best
option for long-term management.
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that we’ve obtained good palliation with the embolization and
remain what we feel is fairly surgically accessible.  
Dr Raymond Dawson (Johannesburg, South Africa). I’m sure
you’re aware of the fact that in dural AVMs they find it now neces-
sary to embolize the venous side of the circulation as well. Do you
find it necessary to occlude the venous drainage in these patients?
Are you aware of any work that’s been done in that regard? 
Dr Jacobowitz. I’m aware of what you’re alluding to. In
almost all of these embolizations, it’s been obviously through the
arterial side. And when the cyanoacrylates are injected, they really
act as a glue. They so rapidly polymerize that they don’t move off
into the venous outflow tract, and we’ve had good success with
that alone. We’ve not routinely occluded the venous side of these. 
Dr Harry R. Schanzer (New York, NY). Sclerosis with alcohol
venous malformations with has been reported to produce in a few
cases spasm of the pulmonary artery and cardiac arrest. Have you
seen any of these things? Do you have any recommendation? 
Dr Jacobowitz. We have not seen that. I certainly would
emphasize for the audience that we only use alcohol for primar-
ily venous malformations because it’s a low-flow lesion and the
alcohol does not move off. There have been reports of using
absolute alcohol for arteriovenous malformations, and there
have been skin sloughing and extensive organ damage because
one can’t control that agent and it can dissipate to other organs
and is extremely caustic.
Dr Kevin G. Burnand (London, UK). We’ve looked back at
the arteriovenous malformations within the limb, and we’ve come
to very much the same conclusion that you have. Embolization is
a form of palliation; it’s not a cure. What I wasn’t clear on from
your data was how many you’d actually repeated CT scans and
MRIs in. Was it in all of them? And how many of them still had
an arteriovenous malformation that was present? You alluded to it
in your conclusions, but you weren’t precise in your results. 
Dr Glenn R. Jacobowitz. Twenty-six out of the 35 had some
imaging study in the postintervention period. In almost all of
them there is some evidence of the malformation still present,
although it’s now smaller and asymptomatic. So we have not
obliterated it completely. 
Dr Burnand. Well, what I’d suggest is that it would be very
nice if you came back in 5 years and told us how many had
recurred, because your follow-up time seemed very short when
you consider the long period that you’ve been enrolling patients
into the study. 
Dr Jonathan B. Towne (Milwaukee, Wis). What are the fac-
tors that cause you to do an operative intervention in these
patients? They present with a myriad of symptoms, and what leads
you to operate on them? 
Dr Jacobowitz. It’s actually a fairly infrequent occurrence.
They’re usually for lesions that are isolated to a single organ, such
as the uterus or the gluteal muscle. So they essentially are lesions
DISCUSSION
